ConCallIQ
Go Pro
GLENMARK Diversified 30 Oct 2025

Glenmark Pharmaceuticals Limited — Q2 FY26

Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to INR 6,047 crore, driven by the ISB 2001 out-licensing income.

bullish high
Compare with...
Revenue ₹6,047 Cr +76%
EBITDA
PAT ₹610 Cr
EBITDA Margin
Duration
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

India distribution disruption from GST change

The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales. While management expects normalization, future regulatory changes could again disrupt the three-tier model.

medium · management_commentary
R

Recurrence of legacy balance sheet issues

Analysts questioned the frequency of write-offs (Monroe, litigation, India). Management assured no further corrections, but past unpredictability raises concerns about controls.

medium · analyst_question
R

Litigation cash outflows still pending

Management confirmed litigation cash outflows of slightly less than INR 800 crore over the next few years, which could pressure cash flows if not managed.

low · analyst_question